Casas Terrón E, Mari Ruiz M, Molina Andreu E
Servicio Análisis Clínicos, Hospital Dr. Peset, Valencia, España.
Arch Esp Urol. 1993 Mar;46(2):99-103.
The tumor marker study attempts to make a diagnosis before the clinical diagnosis. We have studied some of these tumor markers (PSA, PAP and acid phosphatase) in 97 patients who suffered from benign prostatic hypertrophy, prostatic cancer and other non-prostatic pathologies. PSA appears to be the best marker, as reported in the literature. The sensitivity and specificity for two different cut off levels (5 and 10 ng/ml) were analyzed in order to determine the best. The statistical analysis was done by the chi-square method. The differences between the tumor markers were not significant for sensitivity. PSA appears to be more sensitive than PAP. Although there are no significant differences for sensitivity between both cut-off levels, and between PSA and PAP. We consider that the 10 ng/ml cut off is better assuming we will have a higher percentage of specificity (p < 0.05).
肿瘤标志物研究试图在临床诊断之前做出诊断。我们对97例患有良性前列腺增生、前列腺癌和其他非前列腺疾病的患者进行了其中一些肿瘤标志物（前列腺特异性抗原、前列腺酸性磷酸酶和酸性磷酸酶）的研究。正如文献报道的那样，前列腺特异性抗原似乎是最佳标志物。为了确定最佳值，分析了两种不同临界值水平（5和10纳克/毫升）的敏感性和特异性。采用卡方方法进行统计分析。肿瘤标志物之间的敏感性差异不显著。前列腺特异性抗原似乎比前列腺酸性磷酸酶更敏感。尽管两种临界值水平之间以及前列腺特异性抗原和前列腺酸性磷酸酶之间的敏感性没有显著差异。我们认为，假设我们将有更高的特异性百分比（p<0.05），10纳克/毫升的临界值更好。
